Identification of claudin-3 as a candidate biomarker associated with gastric precancerous lesions: a multi-algorithm transcriptomic study with clinical protein-level validation

Objectives This study aimed to identify transcriptomic biomarkers for gastric low-grade intraepithelial neoplasia (LGIN), validate the lead candidate at the protein level in clinical LGIN biopsy specimens, and preliminarily evaluate its expression in intestinal metaplasia (IM). Methods Differentially expressed genes between chronic gastritis and LGIN in GSE130823 were screened using least absolute shrinkage and selection operator (LASSO), support vector machine–recursive feature elimination (SVM-RFE), and weighted gene co-expression network analysis (WGCNA). The lead candidate was validated in GSE55696 and subsequently evaluated by immunohistochemistry in clinical LGIN biopsies. Its expression in chronic atrophic gastritis with intestinal metaplasia (CAG-IM) tissues and an in vitro IM model was examined exploratorily. Results Among 328 differentially expressed genes, claudin-3 ( CLDN3 ) was the sole candidate shared by all three feature-selection methods and distinguished LGIN from chronic gastritis with areas under the receiver operating characteristic curves (AUCs) of 0.938 and 0.903 in the training and validation datasets, respectively. At the protein level, CLDN3 expression was significantly higher in LGIN than in chronic superficial gastritis (CSG) (adjusted p=0.005) and distinguished LGIN from CSG with an AUC of 0.804 (95 % confidence interval [CI], 0.646–0.962). The LGIN vs. CSG difference remained significant after adjustment for Helicobacter pylori ( H. pylori ) status, age, and sex. Exploratory analyses showed that CLDN3 was also elevated in CAG-IM tissues and the in vitro IM model. Conclusions This study identified and validated CLDN3 as a candidate biomarker for LGIN. Its concordant upregulation in CAG-IM tissues additionally suggests that CLDN3 may serve as a broader marker across the gastric precancerous continuum. The persistence of the LGIN vs. CSG difference after accounting for H. pylori status and in H. pylori -negative specimens argues against H. pylori -associated inflammation as a major confounder of the observed CLDN3 elevation.

Authors

Institutions

Publication Details

Journal
ONCOLOGIE
Published
2026-11-18
DOI
https://doi.org/10.1515/oncologie-2026-0260
Primary Topic
Gastric Cancer Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Identification of claudin-3 as a candidate biomarker associated with gastric precancerous lesions: a multi-algorithm transcriptomic study with clinical protein-level validation

Lijing Bao, Fengyun Guo, Qingqing Zhang, Ruiying Zhang et al.
1 links
ONCOLOGIE
Gastric Cancer Management and Outcomes
article

Identification of claudin-3 as a candidate biomarker associated with gastric precancerous lesions: a multi-algorithm transcriptomic study with clinical protein-level validation

Lijing Bao, Fengyun Guo, Qingqing Zhang, Ruiying Zhang, Tai Zhang, Ping Wang, Di Wu
article en

Abstract

Objectives This study aimed to identify transcriptomic biomarkers for gastric low-grade intraepithelial neoplasia (LGIN), validate the lead candidate at the protein level in clinical LGIN biopsy specimens, and preliminarily evaluate its expression in intestinal metaplasia (IM). Methods Differentially expressed genes between chronic gastritis and LGIN in GSE130823 were screened using least absolute shrinkage and selection operator (LASSO), support vector machine–recursive feature elimination (SVM-RFE), and weighted gene co-expression network analysis (WGCNA). The lead candidate was validated in GSE55696 and subsequently evaluated by immunohistochemistry in clinical LGIN biopsies. Its expression in chronic atrophic gastritis with intestinal metaplasia (CAG-IM) tissues and an in vitro IM model was examined exploratorily. Results Among 328 differentially expressed genes, claudin-3 ( CLDN3 ) was the sole candidate shared by all three feature-selection methods and distinguished LGIN from chronic gastritis with areas under the receiver operating characteristic curves (AUCs) of 0.938 and 0.903 in the training and validation datasets, respectively. At the protein level, CLDN3 expression was significantly higher in LGIN than in chronic superficial gastritis (CSG) (adjusted p=0.005) and distinguished LGIN from CSG with an AUC of 0.804 (95 % confidence interval [CI], 0.646–0.962). The LGIN vs. CSG difference remained significant after adjustment for Helicobacter pylori ( H. pylori ) status, age, and sex. Exploratory analyses showed that CLDN3 was also elevated in CAG-IM tissues and the in vitro IM model. Conclusions This study identified and validated CLDN3 as a candidate biomarker for LGIN. Its concordant upregulation in CAG-IM tissues additionally suggests that CLDN3 may serve as a broader marker across the gastric precancerous continuum. The persistence of the LGIN vs. CSG difference after accounting for H. pylori status and in H. pylori -negative specimens argues against H. pylori -associated inflammation as a major confounder of the observed CLDN3 elevation.

ONCOLOGIE
Beijing University of Chinese Medicine (CN), Peking University (CN), First Affiliated Hospital of Heilongjiang University of Chinese Medicine (CN), Xiyuan Hospital (CN), China Academy of Chinese Medical Sciences (CN)
Good health and well-being
Gastric Cancer Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon